Opthea to Participate in the Leerink Partners Global Biopharma Conference
- None.
- None.
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
About Opthea
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.
Authorized for release to ASX by Fred Guerard, CEO
Investor Enquiries
PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media
Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
FAQ
What is Opthea Limited's ticker symbol?
What type of company is Opthea Limited?
Where will Opthea Limited participate in investor meetings?
When will the Leerink Partners Global Biopharma Conference take place?
